Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14717895 | 0.88 | SCN9A (0.31) | SCN9ACYP11B1CYP11B2 | |
| SCHEMBL1660140 | 0.81 | SCN9A (0.35) | SCN9ACYP11B1CYP11B2 | |
| SCHEMBL1660081 | 0.80 | SCN9A (0.34) | SCN9A | |
| SCHEMBL1661829 | 0.80 | KCNN4 (0.33) | SCN9A | |
| SCHEMBL14727905 | 0.79 | AR (0.35) | SCN9ACYP11B1CYP11B2BACE1 | |
| SCHEMBL1660271 | 0.76 | SCN9A (0.30) | SCN9A | |
| SCHEMBL14718267 | 0.75 | KCNN4 (0.32) | SCN9A | |
| SCHEMBL1660033 | 0.75 | LMNA (0.32) | SCN9A | |
| SCHEMBL1660814 | 0.74 | SCN9A (0.31) | SCN9A | |
| SCHEMBL1661602 | 0.73 | SCN9A (0.32) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871796-B2 | Diaryl ether derivatives as notch sparing gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | claimed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | BACE1, BACE2, GSAP | SCN9A 1887/4885CYP11B1 1011/4885CYP11B2 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.